Michael D. Offin, MD
Thoracic Medical Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Mesothelioma
- Lung Cancer
- Targeted Therapy for Lung Cancer
Request an Appointment
About Me
- Co-Director, Mesothelioma Program
- Assistant Attending Physician
I am a board-certified medical oncologist dedicated to caring for people with mesothelioma and lung cancer.
Finding out that you or a family member has a thoracic cancer can be overwhelming. My team and I will help you understand your diagnosis and find the best path forward. I am devoted to providing the highest level of care throughout my patient’s treatment with the goal of providing a personalized approach to improve outcomes and quality of life.
Read more
I care for people with lung cancers (including those patients whose tumors harbor a BRAF alteration) and mesotheliomas (including pleural and peritoneal disease) at the David H. Koch Center for Cancer Care at MSK in Manhattan. As the co-director of the MSK Mesothelioma Program, I work with a comprehensive team of cancer experts from various disciplines to ensure that all of my patients receive individualized and exceptional care.
My research focuses on using laboratory findings to design clinical trials that further the care of my patients. With precision medicine and immunotherapy, people with thoracic cancers, including those with advanced disease, may have several treatment and clinical trial options available. Through my research, and when caring for my patients, I endeavor to analyze available options with a constant eye on evaluating new treatments. I aim to bring the discoveries made by our laboratory researchers to the bedside for the benefit of my patients and beyond.
A thoracic medical oncologist is a cancer doctor who specializes in thoracic (thor-A-sik) cancers. These are cancers that have to do with the chest, including lung, tracheal (windpipe), and thymic (thymus) cancers.
My Specialties
- Mesothelioma
- Lung Cancer
- Targeted Therapy for Lung Cancer
- Clinical Trials
Education
- MD, Rutgers University- New Jersey Medical School
Residencies
- Internal Medicine – Hospital of the University of Pennsylvania
Awards and Honors
- Career Development Award, LUNGevity
- Young Investigator Award, International Mesothelioma Interest Group
- Deans Award, Rutgers University
- Alpha Omega Alpha Member
- Gold Humanism Honor Society Member
- Conquer Cancer Foundation ASCO Merit Award (2018)
Fellowships
- Medical Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Offin sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Clinical Trials
- Clinical Trials Investigated by Dr. Offin
- A Phase 1 Study of KIN-2787 in People With Advanced Cancers
- A Phase 1 Study of VT3989 in People With Mesothelioma
- A Phase 2 Study of Sacituzumab Govitecan in People with Previously Treated Mesothelioma
- A Phase 3 Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed in Inoperable Pleural Mesothelioma
Read more
- Clinical Trials Co-Investigated by Dr. Offin
- A Phase 1 Study of TNG908 in People with Sarcoma, Mesothelioma, or Glioblastoma
- A Phase 2 Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
- A Phase 2 Study of Chemoembolization in People With Non-Small Cell Lung Cancer
- A Phase I Study of Pembrolizumab Immunotherapy and Radiation Therapy in People with Inoperable Pleural Mesothelioma
- A Phase I/II Study of MRTX1719 in People with Solid Tumors
- A Phase II Study Evaluating Stereotactic Body Radiotherapy plus Standard Therapy versus Standard Therapy Alone in Patients with Oligometastatic Breast Cancer or Lung Cancer
- A Phase III Study of Selpercatinib after Surgery or Radiation Therapy for RET Fusion-Positive Lung Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Offin M, Yang SR, Egger J, Jayakumaran G, Spencer RS, Lopardo J, Nash GM, Cercek A, Travis WD, Kris MG, Ladanyi M, Sauter JL, Zauderer MG. Molecular Characterization of Peritoneal Mesotheliomas. J Thorac Oncol. 2022 Mar;17(3):455-460. doi: 10.1016/j.jtho.2021.09.012. Epub 2021 Oct 11. PMID: 34648949; PMCID: PMC8882128.
Offin M, Sauter JL, Tischfield SE, Egger JV, Chavan S, Shah NS, Manoj P, Ventura K, Allaj V, de Stanchina E, Travis W, Ladanyi M, Rimner A, Rusch VW, Adusumilli PS, Poirier JT, Zauderer MG, Rudin CM, Sen T. Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library. Genome Med. 2022 Nov 15;14(1):127. doi: 10.1186/s13073-022-01129-4. PMID: 36380343; PMCID: PMC9667652.
Offin M, De Silva DL, Sauter JL, Egger JV, Yorke E, Adusumilli PS, Rimner A, Rusch VW, Zauderer MG. Multimodality Therapy in Patients With Primary Pericardial Mesothelioma. J Thorac Oncol. 2022 Dec;17(12):1428-1432. doi: 10.1016/j.jtho.2022.08.017. Epub 2022 Sep 6. PMID: 36075530; PMCID: PMC9691618.
Murciano-Goroff YR, Pak T, Mondaca S, Flynn JR, Montecalvo J, Rekhtman N, Halpenny D, Plodkowski AJ, Wu SL, Kris MG, Paik PK, Riely GJ, Yu HA, Rudin CM, Hellmann MD, Land JD, Buie LW, Heller G, Lito P, Yaeger R, Drilon A, Liu D, Li BT, Offin M. Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. Br J Cancer. 2022 Apr;126(6):889-898. doi: 10.1038/s41416-021-01679-1. Epub 2021 Dec 28. PMID: 34963703; PMCID: PMC8927094.
Visit PubMed for a full listing of Dr. Offin’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michael D. Offin discloses the following relationships and financial interests:
-
Mesothelioma Applied Research Foundation
Professional Services and Activities (Uncompensated) -
MJH Life Sciences
Professional Services and Activities
-
Pfizer, Inc.
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].